Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
$790.81
$9.02(1.24%)
At close: 4:00 PM EST
$790.81
$9.02(1.24%)
Day’s Range― - ―
52-Week Range$476.49 - $821.11
Previous CloseN/A
Volume208.99K
Average Volume (3M)733.46K
Market Cap
$83.59B
Enterprise Value$81.75B
Total Cash (Recent Filing)$8.61B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)18.8
Beta0.71
Next Earnings
Apr 30, 2026EPS Estimate
9.14Next Dividend Ex-DateN/A
Dividend Yield0.45%
Share Statistics
EPS (TTM)11.44
Shares Outstanding103,902,660
10 Day Avg. Volume593,291
30 Day Avg. Volume733,463
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue5.70
Enterprise Value/Gross Profit6.68
Enterprise Value/Ebitda14.05
Forecast
1Y Price Target
$873.14Price Target Upside10.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)45.31
Revenue Forecast (FY)$15.71B
Bulls Say, Bears Say
Bulls Say
Core Immunology FranchiseAnalyst highlights Dupixent's long safety record and broad uptake across approved uses, supporting durable revenue and creating a competitive barrier that is difficult for rivals to supplant.
Eye Franchise Product EnhancementsAnalyst points to adoption of a higher-dose Eylea formulation and a pre-filled syringe presentation as catalysts that could stabilize the ophthalmology franchise and boost branded adoption.
Phase 3 Clinical ReadoutAnalyst expects a positive Phase 3 result for the fianlimab plus Libtayo combination in first-line advanced melanoma, which could materially increase market share if an overall survival benefit is demonstrated against existing therapies.
Bears Say
Adjuvant Trial RiskAnalyst warns the adjuvant melanoma program faces tougher biology and prior comparable trial failures, leading to a lower probability of success in that treatment setting.
Biosimilar And Margin PressureAnalyst warns the Eylea franchise is facing increasing biosimilar competition, inventory adjustments, and reduced net selling prices, which could pressure sales and gross margins.
Clinical Competition In MelanomaAnalyst notes the fianlimab plus Libtayo combination must show superior efficacy to the established Opdualag regimen to achieve broad physician adoption, otherwise uptake could be limited.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $821.11 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $83.59B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Apr 30, 2026 which is in 58 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Jan 30, 2026. The company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.736 by $0.704.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.45%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 9.14.
How many shares outstanding does Regeneron have?
Regeneron has 103,902,660 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.44 in its last earnings report, beating expectations of $10.736. Following the earnings report the stock price went down -1.066%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$873.14 (10.41% Upside)
$873.14 (10.41% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 106.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.83%
12-Months-Change
Fundamentals
Return on Equity
14.87%
Trailing 12-Months
Asset Growth
7.15%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial strength (notably Dupixent, EYLEA HD, Libtayo), solid financials, strong cash generation, aggressive shareholder returns, and a deep pipeline with multiple near‑term readouts and regulatory objectives. Headwinds were acknowledged — including EYLEA 2 mg biosimilar pressure, short‑term inventory timing, manufacturing/regulatory risk for the prefilled syringe, patient affordability challenges, and higher R&D and SG&A investments. On balance, the positives — large, high‑growth franchises, robust cash flow, and multiple potentially transformative clinical programs — materially outweigh the near‑term challenges and risks discussed.View all REGN earnings summariesREGN Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
REGN Stock 12 Month Forecast
Average Price Target
$873.14
▲(10.41% Upside)
Technical Analysis
Ownership Overview
1.97% Insiders
24.80% Mutual Funds
9.75% Other Institutional Investors
36.62% Public Companies and Individual Investors